Jefferies says the “market’s thinking is backwards” that a single pivotal drug trial for approvals is a risk to the contract research organizations. A reduction of time to market and cost in development increases research and development return on investment and should increase investment in R&D by pharmaceutical companies, the analyst tells investors in a research note. The pharma industry is not developing all it would like to and regulatory changes to improve the likelihood of success or lower the time and cost to get there should help the get the industry out of its stagnation, contends Jefferies. Contract research organizations under the firm’s coverage are Iqvia (IQV), Icon (ICLR), Fortrea (FTRE) and Medpace (MEDP).
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports
- Iqvia announces strategic collaboration with Amazon Web Services
- Iqvia assumed with an Overweight at Morgan Stanley
- Private Markets: Anthropic to invest $50B in computing infrastructure